Therefore, the potential therapeutic usefulness of PPARα and PPARγ activation in the control of obesity and diabetes-induced chronic (low-grade) inflammation has extensively been studied over the last couple of years using rodents. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.